nodes	percent_of_prediction	percent_of_DWPC	metapath
Desvenlafaxine—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.00263	0.00263	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00262	0.00262	CcSEcCtD
Desvenlafaxine—Fatigue—Thiotepa—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Desvenlafaxine—Dysgeusia—Etoposide—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Desvenlafaxine—Constipation—Thiotepa—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Desvenlafaxine—Irritability—Methotrexate—urinary bladder cancer	0.00253	0.00253	CcSEcCtD
Desvenlafaxine—Convulsion—Cisplatin—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.0025	0.0025	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00249	0.00249	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.00248	0.00248	CcSEcCtD
Desvenlafaxine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00248	0.00248	CcSEcCtD
Desvenlafaxine—Anxiety—Cisplatin—urinary bladder cancer	0.00247	0.00247	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Desvenlafaxine—Hot flush—Doxorubicin—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Desvenlafaxine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Desvenlafaxine—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.00243	0.00243	CcSEcCtD
Desvenlafaxine—Breast disorder—Methotrexate—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Desvenlafaxine—Vertigo—Etoposide—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Etoposide—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Desvenlafaxine—Tachycardia—Cisplatin—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Desvenlafaxine—Convulsion—Etoposide—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Desvenlafaxine—Skin disorder—Cisplatin—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Desvenlafaxine—Insomnia—Gemcitabine—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Desvenlafaxine—Hypertension—Etoposide—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00229	0.00229	CcSEcCtD
Desvenlafaxine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00229	0.00229	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00227	0.00227	CcSEcCtD
Desvenlafaxine—Insomnia—Fluorouracil—urinary bladder cancer	0.00227	0.00227	CcSEcCtD
Desvenlafaxine—Somnolence—Gemcitabine—urinary bladder cancer	0.00227	0.00227	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Desvenlafaxine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00225	0.00225	CcSEcCtD
Desvenlafaxine—Breast disorder—Epirubicin—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Desvenlafaxine—Somnolence—Fluorouracil—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Desvenlafaxine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00222	0.00222	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Desvenlafaxine—Fatigue—Gemcitabine—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Desvenlafaxine—Constipation—Gemcitabine—urinary bladder cancer	0.00218	0.00218	CcSEcCtD
Desvenlafaxine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00218	0.00218	CcSEcCtD
Desvenlafaxine—Asthenia—Thiotepa—urinary bladder cancer	0.00217	0.00217	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Desvenlafaxine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Desvenlafaxine—Tachycardia—Etoposide—urinary bladder cancer	0.00212	0.00212	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00212	0.00212	CcSEcCtD
Desvenlafaxine—Skin disorder—Etoposide—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Desvenlafaxine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Desvenlafaxine—Breast disorder—Doxorubicin—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Desvenlafaxine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Desvenlafaxine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Desvenlafaxine—Dizziness—Thiotepa—urinary bladder cancer	0.002	0.002	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00196	0.00196	CcSEcCtD
Desvenlafaxine—Paraesthesia—Etoposide—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Desvenlafaxine—Weight increased—Epirubicin—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Desvenlafaxine—Weight decreased—Epirubicin—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Desvenlafaxine—Somnolence—Etoposide—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Desvenlafaxine—Epistaxis—Methotrexate—urinary bladder cancer	0.00193	0.00193	CcSEcCtD
Desvenlafaxine—Vomiting—Thiotepa—urinary bladder cancer	0.00193	0.00193	CcSEcCtD
Desvenlafaxine—Rash—Thiotepa—urinary bladder cancer	0.00191	0.00191	CcSEcCtD
Desvenlafaxine—Dermatitis—Thiotepa—urinary bladder cancer	0.00191	0.00191	CcSEcCtD
Desvenlafaxine—Headache—Thiotepa—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Desvenlafaxine—Decreased appetite—Etoposide—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Desvenlafaxine—Fatigue—Etoposide—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Desvenlafaxine—Constipation—Etoposide—urinary bladder cancer	0.00186	0.00186	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00185	0.00185	CcSEcCtD
Desvenlafaxine—Asthenia—Gemcitabine—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Desvenlafaxine—Weight increased—Doxorubicin—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Desvenlafaxine—Epistaxis—Epirubicin—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Nausea—Thiotepa—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Urethral disorder—Methotrexate—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Weight decreased—Doxorubicin—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00175	0.00175	CcSEcCtD
Desvenlafaxine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Desvenlafaxine—Eye disorder—Methotrexate—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Tinnitus—Methotrexate—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Desvenlafaxine—Asthenia—Cisplatin—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00169	0.00169	CcSEcCtD
Desvenlafaxine—Urethral disorder—Epirubicin—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Desvenlafaxine—Epistaxis—Doxorubicin—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Desvenlafaxine—Angiopathy—Methotrexate—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Desvenlafaxine—Immune system disorder—Methotrexate—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Desvenlafaxine—Dizziness—Fluorouracil—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00165	0.00165	CcSEcCtD
Desvenlafaxine—Chills—Methotrexate—urinary bladder cancer	0.00165	0.00165	CcSEcCtD
Desvenlafaxine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Desvenlafaxine—Alopecia—Methotrexate—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Desvenlafaxine—Vomiting—Gemcitabine—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Desvenlafaxine—Mental disorder—Methotrexate—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Desvenlafaxine—Rash—Gemcitabine—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Desvenlafaxine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Desvenlafaxine—Eye disorder—Epirubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Etoposide—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Tinnitus—Epirubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Malnutrition—Methotrexate—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Headache—Gemcitabine—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Desvenlafaxine—Vomiting—Fluorouracil—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Desvenlafaxine—Rash—Fluorouracil—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Desvenlafaxine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Desvenlafaxine—Headache—Fluorouracil—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Desvenlafaxine—Dysgeusia—Methotrexate—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Asthenia—Etoposide—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Angiopathy—Epirubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Immune system disorder—Epirubicin—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Desvenlafaxine—Chills—Epirubicin—urinary bladder cancer	0.00154	0.00154	CcSEcCtD
Desvenlafaxine—Alopecia—Epirubicin—urinary bladder cancer	0.00152	0.00152	CcSEcCtD
Desvenlafaxine—Nausea—Gemcitabine—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Vomiting—Cisplatin—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Vision blurred—Methotrexate—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Mental disorder—Epirubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Rash—Cisplatin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Dermatitis—Cisplatin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Malnutrition—Epirubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Diarrhoea—Etoposide—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Desvenlafaxine—Nausea—Fluorouracil—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Desvenlafaxine—Eye disorder—Doxorubicin—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Desvenlafaxine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Desvenlafaxine—Tension—Epirubicin—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Desvenlafaxine—Dysgeusia—Epirubicin—urinary bladder cancer	0.00146	0.00146	CcSEcCtD
Desvenlafaxine—Nervousness—Epirubicin—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Desvenlafaxine—Angiopathy—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Desvenlafaxine—Dizziness—Etoposide—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Desvenlafaxine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Desvenlafaxine—Vertigo—Methotrexate—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Desvenlafaxine—Chills—Doxorubicin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Desvenlafaxine—Nausea—Cisplatin—urinary bladder cancer	0.00141	0.00141	CcSEcCtD
Desvenlafaxine—Vision blurred—Epirubicin—urinary bladder cancer	0.00141	0.00141	CcSEcCtD
Desvenlafaxine—Alopecia—Doxorubicin—urinary bladder cancer	0.0014	0.0014	CcSEcCtD
Desvenlafaxine—Mental disorder—Doxorubicin—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Desvenlafaxine—Convulsion—Methotrexate—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Desvenlafaxine—Vomiting—Etoposide—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Desvenlafaxine—Malnutrition—Doxorubicin—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Desvenlafaxine—Rash—Etoposide—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Desvenlafaxine—Dermatitis—Etoposide—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Desvenlafaxine—Headache—Etoposide—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Desvenlafaxine—Tension—Doxorubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Desvenlafaxine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Desvenlafaxine—Nervousness—Doxorubicin—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Desvenlafaxine—Vertigo—Epirubicin—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Desvenlafaxine—Syncope—Epirubicin—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Desvenlafaxine—Palpitations—Epirubicin—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Desvenlafaxine—Vision blurred—Doxorubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Desvenlafaxine—Convulsion—Epirubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Desvenlafaxine—Nausea—Etoposide—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Desvenlafaxine—Hypertension—Epirubicin—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Desvenlafaxine—Anxiety—Epirubicin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Desvenlafaxine—Skin disorder—Methotrexate—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Desvenlafaxine—Dry mouth—Epirubicin—urinary bladder cancer	0.00124	0.00124	CcSEcCtD
Desvenlafaxine—Vertigo—Doxorubicin—urinary bladder cancer	0.00124	0.00124	CcSEcCtD
Desvenlafaxine—Syncope—Doxorubicin—urinary bladder cancer	0.00124	0.00124	CcSEcCtD
Desvenlafaxine—Palpitations—Doxorubicin—urinary bladder cancer	0.00122	0.00122	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00122	0.00122	CcSEcCtD
Desvenlafaxine—Shock—Epirubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Desvenlafaxine—Convulsion—Doxorubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Desvenlafaxine—Hypertension—Doxorubicin—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Desvenlafaxine—Tachycardia—Epirubicin—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Desvenlafaxine—Skin disorder—Epirubicin—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Desvenlafaxine—Insomnia—Methotrexate—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Desvenlafaxine—Anxiety—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Desvenlafaxine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Desvenlafaxine—Somnolence—Methotrexate—urinary bladder cancer	0.00116	0.00116	CcSEcCtD
Desvenlafaxine—Dry mouth—Doxorubicin—urinary bladder cancer	0.00115	0.00115	CcSEcCtD
Desvenlafaxine—Decreased appetite—Methotrexate—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Desvenlafaxine—Fatigue—Methotrexate—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Desvenlafaxine—Shock—Doxorubicin—urinary bladder cancer	0.00111	0.00111	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00111	0.00111	CcSEcCtD
Desvenlafaxine—Insomnia—Epirubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Desvenlafaxine—Tachycardia—Doxorubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Desvenlafaxine—Skin disorder—Doxorubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Desvenlafaxine—Paraesthesia—Epirubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00109	0.00109	CcSEcCtD
Desvenlafaxine—Somnolence—Epirubicin—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Desvenlafaxine—Decreased appetite—Epirubicin—urinary bladder cancer	0.00106	0.00106	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Desvenlafaxine—Fatigue—Epirubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Desvenlafaxine—Constipation—Epirubicin—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Desvenlafaxine—Insomnia—Doxorubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Desvenlafaxine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00101	0.00101	CcSEcCtD
Desvenlafaxine—Somnolence—Doxorubicin—urinary bladder cancer	0.001	0.001	CcSEcCtD
Desvenlafaxine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000982	0.000982	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000975	0.000975	CcSEcCtD
Desvenlafaxine—Fatigue—Doxorubicin—urinary bladder cancer	0.000973	0.000973	CcSEcCtD
Desvenlafaxine—Constipation—Doxorubicin—urinary bladder cancer	0.000966	0.000966	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000961	0.000961	CcSEcCtD
Desvenlafaxine—Asthenia—Methotrexate—urinary bladder cancer	0.000936	0.000936	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000899	0.000899	CcSEcCtD
Desvenlafaxine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000892	0.000892	CcSEcCtD
Desvenlafaxine—Asthenia—Epirubicin—urinary bladder cancer	0.000876	0.000876	CcSEcCtD
Desvenlafaxine—Dizziness—Methotrexate—urinary bladder cancer	0.000862	0.000862	CcSEcCtD
Desvenlafaxine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000835	0.000835	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000832	0.000832	CcSEcCtD
Desvenlafaxine—Vomiting—Methotrexate—urinary bladder cancer	0.000829	0.000829	CcSEcCtD
Desvenlafaxine—Rash—Methotrexate—urinary bladder cancer	0.000822	0.000822	CcSEcCtD
Desvenlafaxine—Dermatitis—Methotrexate—urinary bladder cancer	0.000821	0.000821	CcSEcCtD
Desvenlafaxine—Headache—Methotrexate—urinary bladder cancer	0.000817	0.000817	CcSEcCtD
Desvenlafaxine—Asthenia—Doxorubicin—urinary bladder cancer	0.00081	0.00081	CcSEcCtD
Desvenlafaxine—Dizziness—Epirubicin—urinary bladder cancer	0.000807	0.000807	CcSEcCtD
Desvenlafaxine—Vomiting—Epirubicin—urinary bladder cancer	0.000776	0.000776	CcSEcCtD
Desvenlafaxine—Nausea—Methotrexate—urinary bladder cancer	0.000775	0.000775	CcSEcCtD
Desvenlafaxine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000773	0.000773	CcSEcCtD
Desvenlafaxine—Rash—Epirubicin—urinary bladder cancer	0.000769	0.000769	CcSEcCtD
Desvenlafaxine—Dermatitis—Epirubicin—urinary bladder cancer	0.000769	0.000769	CcSEcCtD
Desvenlafaxine—Headache—Epirubicin—urinary bladder cancer	0.000764	0.000764	CcSEcCtD
Desvenlafaxine—Dizziness—Doxorubicin—urinary bladder cancer	0.000747	0.000747	CcSEcCtD
Desvenlafaxine—Nausea—Epirubicin—urinary bladder cancer	0.000725	0.000725	CcSEcCtD
Desvenlafaxine—Vomiting—Doxorubicin—urinary bladder cancer	0.000718	0.000718	CcSEcCtD
Desvenlafaxine—Rash—Doxorubicin—urinary bladder cancer	0.000712	0.000712	CcSEcCtD
Desvenlafaxine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000711	0.000711	CcSEcCtD
Desvenlafaxine—Headache—Doxorubicin—urinary bladder cancer	0.000707	0.000707	CcSEcCtD
Desvenlafaxine—Nausea—Doxorubicin—urinary bladder cancer	0.000671	0.000671	CcSEcCtD
